Measurement of thrombosis and its prevention

British Journal of Clinical Pharmacology

Volumn 54, Issue 1, 2002, Pages 96-100

  Lowe, Gordon D O ^a,b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Therapeutics of West Glasgow Hospitals   (United Kingdom)

Author keywords

Myocardial infarction; Thrombosis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN; PLATELET RECEPTOR 2A BLOCKING AGENT; PLATELET RECEPTOR 2B BLOCKING AGENT; RECEPTOR BLOCKING AGENT; STREPTOKINASE; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN;

ARTERY RUPTURE; BRAIN HEMORRHAGE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSTIPATION; DEEP VEIN THROMBOSIS; DYSPEPSIA; ECHOCARDIOGRAPHY; ECHOGRAPHY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LUNG ANGIOGRAPHY; NAUSEA; PHLEBOGRAPHY; PRIORITY JOURNAL; SCINTISCANNING; THROMBOEMBOLISM; THROMBOSIS; VENOUS STASIS; VOMITING;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOEMBOLISM; THROMBOSIS;

EID: 0036965521     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01626.x     Document Type: Conference Paper

References (24)

1. Scottish Intercollegiate Guidelines Network (SIGN.). Antithrombotic Therapy. A National Clinical Guideline. Edinburgh: SIGN, 1999.
2. Scottish Intercollegiate Guidelines Network (SIGN.). Prophylaxis of Venous Thromboembolism. A National Clinical Guideline. Edinburgh: SIGN, 2002.
3. Hirsh J, Dalen JE, eds. Sixth ACCP. Consensus conference on antithrombotic therapy. Chest 2001; 119(Suppl).
4. Antithrombotic Trialists' Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy: Collaborative meta-analysis of 266 trials involving 200,000 patients at high risk of occlusive vascular disease. Br Med J 2002; 324: 71-86.
5. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin. Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 55: 1295-1302.
6. Lowe GDO. Who should take aspirin for primary prophylaxis of coronary heart disease? Heart, 2001; 85: 245-246.
7. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265-271.
8. Hankey G, Sudlow C, Dunbabin DW. Thienopyridines versus aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomised trials. Stroke 2000; 31: 1779-1784.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
10. Mehta SR, Yusuf S, Peters RG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533.
11. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
12. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001; 88: 672-674.
13. Bousser MG. Antithrombotic strategy in stroke. Thromb Haemostas 2001; 86: 1-7.
14. Goldhaber SZ. Thrombolysis in pulmonary embolism: A debatable indication. Thromb Haemost 2001; 86: 444-451.
15. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: Is there still an indication? Thromb Haemost 2001; 86: 499-508.
16. Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - A consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. JACC 2000; 36: 959-969.
17. Tunstall-Pedoe H. Redefinition of myocardial infarction by a consensus dissembler. JACC 2001; 37: 1472-1473.
18. Wood D, Durrington P. McInnes G, Poulter N, Rees A, Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2): S1-S29.
19. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482.
20. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erthryocyte sedimentation rate, meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000; 21: 515-520.
21. Whinthrup P, Danesh J, Walker M, et al. Von Willebrand factor and coronary heart disease: New prospective study and meta-analysis. Eur Heart J 2002; in press.
22. Lowe GDO, Danesh J, Rumley A, et al. Tissue plasminogen activator antigen and coronary heart disease: New prospective study and meta-analysis. Blood Coagul Fibrinolysis, 2001; 12: A1-2.
23. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: Prospective study and meta-analysis. Circulation 2001; 103: 2323-2327.
24. Lip GYH, Zafiris J, Watson RDS, Bareford D, Lowe GDO, Beevers DG. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-431.